STAT and SMAD signaling in cancer

Histology and Histopathology

Volumn 17, Issue 3, 2002, Pages 887-895

  Iwamoto, T ^a   Oshima, K ^a   Senga, T ^a   Feng, X ^a   Oo, M L ^a   Hamaguchi, M ^a   Matsuda, Satoru ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

APRO TOB; JAK; SMAD; SOCS CIS; STAT

Indexed keywords

APRO6 PROTEIN; CIS PROTEIN; CIS1 PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYTOKINE; DNA; GENE PRODUCT; MH1; MH2; PROTEIN P300; PROTEIN SH2; SMAD PROTEIN; SMAD1 PROTEIN; SMAD4 PROTEIN; SMAD5 PROTEIN; SMAD6 PROTEIN; SMAD7 PROTEIN; SMAD8 PROTEIN; STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; SUPPRESSOR OF CYTOKINE SIGNALING 1; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; BREAST CARCINOMA; CANCER; CANCER CELL; CARCINOGENESIS; CELL FUNCTION; CELL GROWTH; CELL PROLIFERATION; DISEASE MODEL; DNA BINDING; GENE EXPRESSION; GENE TARGETING; HEAD AND NECK CANCER; HUMAN; IN VIVO STUDY; LEUKEMIA; MOLECULAR DYNAMICS; MULTIPLE MYELOMA; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ANIMALS; DNA-BINDING PROTEINS; HUMANS; MODELS, BIOLOGICAL; MODELS, GENETIC; NEOPLASMS; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS;

EID: 0036066956     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis
2. STATs in oncogenesis
3. Molecular cloning of PC3, a putatively secreted protein whose mRNA is induced by nerve growth factor and depolarization
4. Stat3 activation is required for cellular transformation by v-src
5. Stat3 as an oncogene
6. Constitutive activation of JAK1 in Src-transformed cells
7. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl
8. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells
9. Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor beta growth arrest program
10. Specific inhibition of Stat3 signal transduction by PIAS3
11. The p38 MAPK pathway is required for cell growth inhibition of human breast cancer cells in response to activin
12. JAK-STAT signaling activated by Abl oncogenes
13. Stats and gene regulation
14. Characterization of functional domains within Smad4/DPC4
15. STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells
16. Socs1 binds to multiple signalling proteins and suppresses steel factor-dependent proliferation
17. Interaction of human suppressor of cytokine signaling (SOCS)-2 with the insulin-like growth factor-I receptor
18. A new protein containing an SH2 domain that inhibits JAK kinases
19. The tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for smad3 in TGF-beta-induced transcriptional activation
20. Structure and expression of TIS21, a primary response gene induced by growth factors and tumor promoters
21. Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation
22. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells
23. Antagonistic regulation of type I collagen gene expression by interferon-gamma and transforming growth factor-beta. Integration at the level of p300/CBP transcriptional coactivators
24. TGFbeta1 represses proliferation of pancreatic carcinoma cells which correlates with Smad4-independent inhibition of ERK activation
25. Blocking transforming growth factor beta signaling in transgenic epidermis accelerates chemical carcinogenesis: A mechanism associated with increased angiogenesis
26. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro
27. Cloning of the mouse BTG3 gene and definition of a new gene family (the BTG family) involved in the negative control of the cell cycle
28. Involvement of the p38 mitogen-activated protein kinase pathway in transforming growth factor-betas-induced gene expression
29. Interaction and functional cooperation of PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline Calpha promoter
30. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest
31. Smads mediate signaling of the TGFbeta superfamily in normal keratinocytes but are lost during skin chemical carcinogenesis
32. TGF-beta signalling from cell membrane to nucleus through SMAD proteins
33. Nuclear integration of JAK/STAT and Ras/AP-1 signaling by CBP and p300
34. Mutations in the SMAD4/DPC4 gene in juvenile polyposis
35. Cytokine receptor signalling
36. STATs: Signal transducers and activators of transcription
37. Tob2, a novel anti-proliferative Tob/BTG1 family member, associates with a component of the CCR4 transcriptional regulatory complex capable of binding cyclin-dependent kinases
38. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members
39. Mutations of the Smad4 gene in acute myelogeneous leukemia and their functional implications in leukemogenesis
40. Cooperation between STAT3 and c-jun suppresses Fas transcription
41. The JAK-inhibitor, JAB/SOCS-1 selectively inhibits cytokine-induced, but noT V-Src induced JAK-STAT activation
42. TGF-beta-stimulated cooperation of smad proteins with the coactivators CBP/p300
43. The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2
44. The Elongin BC complex interacts with the conserved SOCS-box motif present in members in the SOCS, ras, WD-40 repeat, and ankyrin repeat families
45. Negative regulators of cytokine signaling
46. SOCS: Physiological suppressors of cytokine signaling
47. Inhibition of Stat1-mediated gene activation by PIAS1
48. Inactivation of the type II TGF-betas receptor in colon cancer cells with microsatellite instability
49. Transcriptional control by the TGF-beta/Smad signaling system
50. Tob, a novel protein that interacts with p185erB2, is associated with anti-proliferative activity
51. In search of a function for the TIS21/PC3/BTG1/TOB family
52. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor
53. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-1
54. Structure and function of a new STAT-induced STAT inhibitor
55. Synergistic signaling in fetal brain by STAT3-Smad1 complex bridged by p300
56. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis
57. Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: Tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines
58. Dissection of signaling cascades through gp130 in vivo: Reciprocal roles for STAT3- and SHP2-mediated signals in immune responses
59. Transforming growth factor-beta and ciliary neurotrophic factor synergistically induce vasoactive intestinal peptide gene expression through the cooperation of Smad, STAT, and AP-1 sites
60. BTG1, a member of a new family of antiproliferative genes
61. Homozygous deletion map at 18q21.1 in pancreatic cancer
62. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes
63. Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2
64. Mullerian inhibiting substance inhibits breast cancer cell growth through an NFKappa B-mediated pathway
65. JAK/STAT3-dependent activation of the RalGDS/Ral pathway in M1 mouse myeloid leukemia cells
66. The inhibitory effects of transforming growth factor beta1 on breast cancer cell proliferation are mediated through regulation of aberrant nuclear factor-kappaB/Rel expression
67. A family of cytokine-inducible inhibitors of signalling
68. CIS1, a cytokine-inducible SH2 protein, suppresses BCR/ABL-mediated transformation. Involvement of the ubiquitin proteasome pathway
69. SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor
70. Stat3 activation by Src induces specific gene regulation and is required for cell transformation
71. Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein
72. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway
73. RaI-GTPases mediate a distinct downstream signaling pathway from Ras that facilitates cellular transformation
74. Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction
75. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop
76. Negative regulation of cytokine signaling pathways
77. Negative regulation of BMP/Smad signaling by Tob in osteoblasts
78. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity
79. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors
80. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein
81. Transforming growth factor-beta repression of matrix metalloproteinase-1 in dermal fibroblasts involves smad3
82. The tumor suppressor Smad4/DPC 4 as a central mediator of Smad function
83. Activation of Stat3 in v-Src-transformed fibroblasts requires cooperation of Jak1 kinase activity
84. Smad3 mutant mice develop metastatic colorectal cancer